Phase 1 Trial of Temozolomide Plus Irinotecan Plus O6-Benzylguanine in Adults With Recurrent Malignant Glioma.

Authors :: Quinn, Jennifer A.
Jiang, Sara Xiaoyin
Reardon, David A.
Desjardins, Annick
Vredenburgh, James J.
Gururangan, Sridharan
Sampson, John H.
McLendon, Roger E.
Herndon II, James E.
Friedman, Henry S.
Source :: Cancer (0008543X). 7/1/2009, Vol. 115 Issue 13, p2964-2970. 7p. 1 Chart.
Publication Year :: 2009
Abstract: The article presents a clinical trial in patients with recurrent or progressive malignant glioma (MG). The trial was intended to find the maximum tolerated dose (MTD) and toxicity of irinotecan (CPT-11) when distributed with O6-benzylguanine and temozolomide (TMZ). The trial shows that in both strata, the dose-fixing toxicities were hematologic and included in four leukopenia, neutropenia, thrombocytopenia and febrile neutropenia.

Subjects :: *CLINICAL trials
*NERVOUS system tumors
*NEUTROPENIA
*FEBRILE neutropenia
*THROMBOCYTOPENIA
*GLIOMAS

Full Text Access

Tools